Vaccination HesitancyNCT05804825
Testing the Persuasiveness of Pro-inoculation Arguments
A study testing Argument inoculation messages and Simple forewarning message in people with Vaccination Hesitancy and Human Papillomavirus Vaccination, run by University of Pennsylvania at 1 site in United States.
Trial summary
The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vaccination Hesitancy, Human Papillomavirus Vaccination, Vaccine Refusal
- What is being tested?
- Argument inoculation messages and Simple forewarning message
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 523 participants
- Where
- 1 siteUnited States
- Study dates
- 4 May 2023to 24 May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or female parent or legal guardian of an adolescent ages 7-10
- Age eligible child has not yet received any doses of the HPV vaccine
- Resides in the United States
- English speaking
- Completed informed consent
Who cannot join
- Unable to read English at a 6th grade literacy level
- Age < 18
- Does not have a child within the age range of 7-10
- Age-eligible child has received 1 or more doses of the HPV vaccine
- Does not have a social media account on one or more of the following platforms OR does not read online news stories: Twitter, Instagram, YouTube, Facebook (feasibility testing only - survey participation will not have this exclusion criteria)
- Unwilling or unable to provide informed consent to study participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Message Testing Protocol for Misinformation Concerns
The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.
- Being tested
- Argument inoculation messages, Simple forewarning message
- Keywords
- misinformation, HPV vaccine, vaccine hesitancy
- Medical subject headings
- Vaccination Hesitancy, Vaccination Refusal, Communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Argument inoculation messagesBehavioural
Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
Simple forewarning messageBehavioural
Participants will be presented with a simple forewarning message.
| Study group | Role | What they receive |
|---|---|---|
| Simple forewarning message | Active comparator | Participants will receive a simple short forewarning message to read and rate. Receives: Behavioral: Simple forewarning message |
| Argument inoculation messages | Experimental | Participants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate. Receives: Behavioral: Argument inoculation messages |
What is being measured
The primary outcome is the main question the study is designed to answer.
Argument strength/PME
Arguments will be rated for their argument strength/message effectiveness
Measured: The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.
Misinformation believability
A rating of the believability/ credibility of vaccine misinformation
Measured: The outcome measure will be assessed immediately after the participant has viewed each misinformation message during the survey.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2023
- Study start4 May 2023
- Primary completion24 May 2023
- Study completion24 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vaccination HesitancyStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized discrete choice modeling experiment design
- Masking
- None (open label)
- Enrolment
- 523 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05804825
- Sponsor's protocol ID
- dfjgehea
- Status last verified
- Jul 2023
- First submitted
- 20 Oct 2022
- Last updated
- 11 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Message Testing Protocol for Misinformation Concerns
- ClinicalTrials.gov ID
- NCT05804825
- Acronym / sponsor ID
- dfjgehea
- Keywords
- misinformation, HPV vaccine, vaccine hesitancy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 523 participants (actual)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Study start
- 4 May 2023 (actual)
- Primary completion
- 24 May 2023 (actual)
- Study completion
- 24 May 2023 (actual)
- First posted
- 7 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will recruit a national sample of parents of 7-10-year-olds to complete an argument strength ranking for either a simple forwarding message or between 3 and 6 randomly selected arguments from an overall set of 50 to 100 messages identified from various online sources. Parents will rate each message they see on measures of perceived argument strength/PME. Parents will also answer sociodemographic questions and then rank the believability of a set of anti-vaccine messages identified in a different study. Study findings will contribute valuable information to understanding the effectiveness of different inoculation messages.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- randomized discrete choice modeling experiment design
| Arm | Type | Receives |
|---|---|---|
| Simple forewarning message | Active comparator | Behavioral: Simple forewarning messageParticipants will receive a simple short forewarning message to read and rate. |
| Argument inoculation messages | Experimental | Behavioral: Argument inoculation messagesParticipants will view a random sample of 3 text-only short messages (from a corpus of 100 arguments) to read and rate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female parent or legal guardian of an adolescent ages 7-10
- Age eligible child has not yet received any doses of the HPV vaccine
- Resides in the United States
- English speaking
- Completed informed consent
Key exclusion criteria (6 listed)
- Unable to read English at a 6th grade literacy level
- Age < 18
- Does not have a child within the age range of 7-10
- Age-eligible child has received 1 or more doses of the HPV vaccine
- Does not have a social media account on one or more of the following platforms OR does not read online news stories: Twitter, Instagram, YouTube, Facebook (feasibility testing only - survey participation will not have this exclusion criteria)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Argument inoculation messagesParticipants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages. | Behavioural | Argument inoculation messages |
| Simple forewarning messageParticipants will be presented with a simple forewarning message. | Behavioural | Simple forewarning message |
Primary outcome
Argument strength/PME
Time frame: The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.
Arguments will be rated for their argument strength/message effectiveness
Misinformation believability
Time frame: The outcome measure will be assessed immediately after the participant has viewed each misinformation message during the survey.
A rating of the believability/ credibility of vaccine misinformation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2023.
Related trials for Vaccination Hesitancy
Not yet recruiting
Conversational AI for Adult Flu Vaccination Decisions
Influenza, Human, Vaccine Hesitancy
Recruiting
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
Acute Coronary Syndrome, Heart Failure
Not yet recruiting
Development and Evaluation of a Digital Educational Intervention to Improve Vaccine Confidence and Communication Among Registered Nurses: Protocol for a Randomized Controlled Trial (VaxNurse-RCT).
Vaccine Hesitancy, Vaccine Acceptance
Active, not recruiting
Communication Strategies to Increase HPV Vaccinations
Papilloma Viral Infection, Vaccine Hesitancy
Not yet recruiting
Parents' Knowledge and Attitudes Towards Vaccinating Their Children
Vaccine Hesitancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Argument inoculation messages and Simple forewarning message in people with Vaccination Hesitancy and Human Papillomavirus Vaccination, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Argument strength/PME (time frame: The outcome measure will be assessed immediately after the participant has viewed each pro-HPV vaccine message if they are in the multiple message condition, or the simple message if they are in the simple message condition stimuli during the survey.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2023.